Atlas Trials

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Clinical trial NCT03823118 · COMPLETED

Trial details

NCT number
NCT03823118
Sponsor
Taizhou Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer Recurrent
Start date
2019-03-01
Primary completion
2020-06-28
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.